2014 seminars

16 December 2014

Professor Michiel Vermeulen
Radbound Institute for Molecular Life Sciences
University of Nijmegen, the Netherlands 

‘Quantitative interaction proteomics for epigenetics’ 

11 December

Professor José-Luis Gómez-Skarmeta
CSIC-Universidad Pablo de Olavide-Junta de Andalucia
Seville, Spain

'3D chromatin organization of regulatory information during development, evolution and in human diseases’ 

27 November

Ellen Fortini
Harry Perkins Institute of Medical Research

‘Identifying the RNA targets of DBHS proteins to give insights into the internal organisation and function of a nuclear IncRNA:Protein complex'

24 November

Neil Fleshner
Head of Division of Urology, Princess Margaret Hospital, University of Toronto
Department of Surgery, University of Toronto

'Diet, Lifestyle, Epigenetics and Prostate Cancer'

6 November

Malcolm Walkinshaw
Director of the Centre for Translational and Chemical Biology
University of Edinburgh

'Divergent Allosteric Mechanisms in Two Classes of Potential Drug Targeted Proteins’'

30 October

Stefan Rose-John
Department of Biochemistry
Kiel Medical School

'ADAM17 in the Regulation of Inflammation and Cancer' 

27 October

Adam Giangreco
University College London

‘The best laid schemes of airway repair’

23 October

John Rasko
Director of the Department of Cell & Molecular Therapies
Royal Prince Alfred Hospital

 ‘Intron retention provides a hidden layer of gene expression control’

20 October

Sophie Jamal
Scientist, Women’s College Research Institute
Division of Endocrinolgy, Women’s College Hospital
Division of Endocrinology & Metabolism, University of Toronto

‘Calcium for Chronic Kidney Disease – Too much of a good thing’

9 October

Meenhard Herlyn
Caspar Wistar Professor of Melanoma Research
Director of the Melonoma Research Center
The Wistar Institute in Philadelphia

'The many paths to therapy resistance in melanoma' 

3 October

Johannes Nossent
Winthrtop Professor of Rheumatology
University of Western Australia

‘Thrombopoietin and the control of hematopoietic stem cells and platelet production’

2 October

Warren Alexander
Joint Head of the Cancer and Haematology Division
Laboratory Head Walter and Eliza Hall Institute of Medical Research

‘Neutrophil cytoplasmic autoantibodies in systemic vasculitis: friend or foe?’

25 September

Stephan Schuster
Professor of Environmental Genomics
Research Director at SCELSE
Nanyang Technological University, Singapore


'How ethnicity matters for medical genomics'

19 September

Jonathan Fitzgerald
Vice President, Discovery
Merrimack Pharmaceuticals

'Translating Insights from Biological Systems into Drug & Diagnostic Development Strategies'

5 September

Axel Kallies
Laboratory Head, Molecular Immunology Division
Walter and Eliza Hall Institute of Medical Research

‘T cells: from clonal selection and Burnet to sugar and fat’

4 September

Ross Hannan
Head of the Oncogenic Signaling and Growth Control
Program in the Division of Research
Peter MacCallum Cancer Centre

'The Rise of the Nucleolus as a Target for the Treatment of Cancer: ‘mille viae ducunt homines per saecula Ribosoma’

28 August

Grant Logan
Gene Therapy Unit
Children’s Medical Research Institute

'Adeno-associated virus: an essential component in the toolkit for molecular manipulation of the liver'

21 August

Nadia Rosenthal
Founding Director of the Australian Regenerative Medicine
Monash University

 'Immune regulation of regeneration'

19 August

David Singh
Clinical Pharmacology and Respiratory Medicine
The University of Manchester, England

'Dual bronchodilation and the changing landscape for COPD'

14 August

Stuart Hodgetts
Director of the Spinal Cord Repair Laboratory
School of Anatomy, Physiology & Human Biology
The University of Western Australia

Toby Merson
Laboratory Head
Multiple Sclerosis Division
Florey Institute of Neuroscience and Mental Health, Victoria

'Strategies at UWA for the Repair of the Injured Spinal Cord'


'New Insights into the function and regeneration of oligodendrocytes in the brain'

7 August

Michael Matthews
Chair of Biochemistry & Molecular Biology
Rutgers-New Jersey Medical School

Stuart Shapiro
Medical Program Officer and Team Leader for Vaccine Discovery
Preclinical Research & Development Branch
Vaccine Research Program, Division of AIDS (DAIDS), NIAID

'Apoptosis and eIF5A in a novel anti-HIV drug therapy' and 'HIV/AIDS Vaccine Challenges'

28 July

Mark Hutchinson
Australian Research Council Research Fellow
School of Medical Sciences
University of Adelaide

The TOLL of knowing you are sick: implications for pain and addiction

24 July

Professor Darryl Knight
Head of School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine
The University of Newcastle

What’s the magic number behind epithelial cell differentiation, innate immunity and asthma: (p)300

21 July

Douglas Bakkum
Group Leader
Department of Biosystems Science and Engineering
ETH Zurich

 Electrical imaging of axon function using an 11,000-electrode CMOS circuit

17 July

Emily Todd
PhD Student, Neurogenetics Laboratory
Harry Perkins Institute of Medical Research

Investigation of the genetic causes of foetal akinesias and motor neuron disease

3 July

Professor Christobel Saunders
Winthrop Professor of Surgical Oncology
University of Western Australia

Cancer Research across the Continuum – and into practice
26 June

Professor Bruce Robinson
National Centre for Asbestos Related Diseases

Our journey using new approaches to cancer – studies using proteomics, animal models, gene sequencing and immunotherapy
19 June

Professor Nigel Bunnett
Professor of Pharmacology and Medicine
Monash University

Endosomes as Platforms for the Signalling Train to Pain and Inflammation
12 June

Kyle Yau
PhD Student, Neurogenetics Laboratory
Harry Perkins Institute of Medical Research

Application of classical and next generation sequencing techniques to gene discovery and diagnostics in neurogenetic disorders
5 June

Dr Janice Lam
Research Associate, Laboratory for Cell Signalling
Harry Perkins Institute of Medical Research

A novel mediator of ErbB signalling cascade: friend or foe?
29 May

Dr Robert Bryson-Richardson
School of Biological Sciences
Monash University

Determination of the Mechanism of Disease in Nemaline and Myofibrillar Myopathies
27 May

Dr Nancy Allbritton
Department of Chemistry, Department of Pharmacology
University of North Carolina

Microdevices for Cells, Tissues, and Organs
12 May

Eric Olson
Professor and Chair of the Department of Molecular Biology
University of Texas Southwestern Medical Center, Dallas

New Molecules and Mechanisms of Muscle Development, Disease and Regeneration
6 May

Dr Robin Hesketh
Department of Biochemistry
University of Cambridge

Decision Time for Cancer Therapy
8 April

Professor Mariapia Degli-Esposti
Director of Research
Lions Eye Institute

Mechanisms regulating immune responses during viral infection: defining the key players and their roles
1 April

Professor Sharad Kumar
Co-Director, Centre for Cancer Biology
University of South Australia

Molecular mechanisms regulating cell death
25 March

Dr Mark Shackleton
Medical Oncologist & Melanoma Research Laboratory Group Leader
Peter MacCallum Cancer Centre

How do Melanomas grow? Biological paradigms of cancer heterogeneity and progression
18 March

Professor Wayne Tilley
Dame Roma Mitchell Cancer Research Laboratories
University of Adelaide

The Androgen Receptor: a double sided sword in breast cancer?
13 March

Dr Julian Heng
Australian Regenerative Medicine Group

Making sense of genetic mutations implicated in brain developmental disorder
4 March

Professor Stephen Hill
School of Life Sciences
University of Nottingham

Seeing is believing - Monitoring ligand-receptor binding in time and space
4 March

Dr Erica Sloan
Monash University

Blocking stress response pathways to stop cancer: imaging neural-tumour dynamics
17 February

Professor Lisa Coussens
Chair of Cell and Developmental Biology
Knight Cancer Institute
Oregon Health and Sciences University

Infalmmation and Cancer: Immune cells as targets for anti-cancer therapy
9 January

Professor Des Richardson
Director of the Molecular Pharmacology and Pathology Program
University of Sydney

How to trick a transporter to kill drug resistance tumour cells: Targeting the lysosome and P-glycoprotein
Back To Top